Display options
Cite
Mravčík V, Strada L, Stolfa J, et al. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence. 2013;7:1067-75doi: 10.2147/PPA.S49113.
Mravčík, V., Strada, L., Stolfa, J., Bencko, V., Groshkova, T., Reimer, J., & Schulte, B. (2013). Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient preference and adherence, 71067-75. https://doi.org/10.2147/PPA.S49113
Mravčík, Viktor, et al. "Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review." Patient preference and adherence vol. 7 (2013): 1067-75. doi: https://doi.org/10.2147/PPA.S49113
Mravčík V, Strada L, Stolfa J, Bencko V, Groshkova T, Reimer J, Schulte B. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence. 2013 Oct 17;7:1067-75. doi: 10.2147/PPA.S49113. PMID: 24204126; PMCID: PMC3804540.
Copy Download .nbib Format: NLM
Share it on

Patient Prefer Adherence. 2013 Oct 17;7:1067-75. doi: 10.2147/PPA.S49113.

Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review.

Patient preference and adherence

Viktor Mravčík, Lisa Strada, Josef Stolfa, Vladimir Bencko, Teodora Groshkova, Jens Reimer, Bernd Schulte

Affiliations

  1. National Monitoring Centre for Drugs and Drug Addiction, Prague, Czech Republic ; Department of Addictology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.

PMID: 24204126 PMCID: PMC3804540 DOI: 10.2147/PPA.S49113

Abstract

INTRODUCTION AND METHODS: Hepatitis C virus (HCV) infections are highly prevalent amongst people who inject drugs (PWID). Despite well documented evidence of its effectiveness, suggested cost-effectiveness, and potential to reduce HCV prevalence rates, the uptake of antiviral HCV treatment by PWID is low. This nonsystematic literature review describes factors associated with the uptake, adherence, and efficacy of HCV treatment among PWID and discusses strategies to increase their uptake of treatment.

RESULTS: Low HCV treatment uptake among PWID is associated with a number of patient-related and provider-related barriers. Beliefs and fears about low efficacy and adverse effects on the patient's part are common. A substantial number of factors are associated with the chaotic lifestyle and altered social functioning of PWID, which are often associated with decompensation or relapsing into drug addiction. This may lead to perceived low adherence with treatment and low efficacy on the provider's part too, where lack of support, inadequate management of addiction, and other drug-related problems and poor treatment of side effects have been described. Practical issues such as the accessibility of treatment and finances also play a role. Strategies to improve the HCV treatment rate among PWID involve pretreatment management and assessment, a multidisciplinary approach, management of side effects, and enhanced education and counseling.

CONCLUSION: Specific factors are associated with poorer treatment outcomes in PWID on the side of both the patient and the treatment system. However, given that PWID can achieve treatment adherence and sustained virologic response rates comparable with those in nondrug users, drug use per se should not be considered a criterion for exclusion from treatment. Further development of measures leading to higher uptake of treatment and adherence in PWID and appropriate adaptation of HCV treatment guidelines represent important tools in this regard.

Keywords: adherence; efficacy; hepatitis C virus; people who inject drugs; treatment uptake

References

  1. Clin Microbiol Rev. 2000 Apr;13(2):223-35 - PubMed
  2. Dig Liver Dis. 2007 Sep;39 Suppl 1:S4-7 - PubMed
  3. Drug Alcohol Depend. 2010 Aug 1;110(3):228-33 - PubMed
  4. AIDS. 2000 Mar 31;14(5):605-11 - PubMed
  5. Hepatology. 2006 Feb;43(2):250-6 - PubMed
  6. J Hepatol. 2011 Jul;55(1):76-85 - PubMed
  7. Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S304-12 - PubMed
  8. Lancet. 2011 Aug 13;378(9791):571-83 - PubMed
  9. Clin Infect Dis. 2013 Mar;56(6):806-16 - PubMed
  10. Eur J Gastroenterol Hepatol. 2006 Feb;18(2):159-66 - PubMed
  11. Drug Alcohol Rev. 2008 Mar;27(2):152-9 - PubMed
  12. Gastroenterology. 2008 Aug;135(2):451-8 - PubMed
  13. J Subst Abuse Treat. 2007 Jul;33(1):99-105 - PubMed
  14. N Engl J Med. 2001 Jul 19;345(3):211-5 - PubMed
  15. J Addict Med. 2010 Mar;4(1):20-6 - PubMed
  16. Drug Alcohol Depend. 2010 Mar 1;107(2-3):244-9 - PubMed
  17. Gastroenterol Res Pract. 2010;2010: - PubMed
  18. Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S297-303 - PubMed
  19. Semin Liver Dis. 2011 Nov;31(4):331-9 - PubMed
  20. Can J Gastroenterol. 2011 Mar;25(3):135-9 - PubMed
  21. Hepatology. 2007 Oct;46(4):991-8 - PubMed
  22. J Hepatol. 2006 Jan;44(1):97-103 - PubMed
  23. Int J Drug Policy. 2007 Oct;18(5):374-80 - PubMed
  24. Hepatology. 2006 May;43(5):954-60 - PubMed
  25. Gastroenterology. 2006 Aug;131(2):451-60 - PubMed
  26. Epidemiol Infect. 2009 Sep;137(9):1255-65 - PubMed
  27. Hepatology. 2012 Apr;55(4):1058-69 - PubMed
  28. Gastroenterology. 2003 Jul;125(1):80-8 - PubMed
  29. Scand J Gastroenterol Suppl. 1996;218:106-15 - PubMed
  30. Clin Infect Dis. 2009 Aug 15;49(4):561-73 - PubMed
  31. J Viral Hepat. 2010 Dec;17(12):839-44 - PubMed
  32. Hepatology. 2001 Jul;34(1):188-93 - PubMed
  33. Int J Drug Policy. 2007 Oct;18(5):352-8 - PubMed
  34. Drug Alcohol Depend. 2008 Jan 11;93(1-2):141-7 - PubMed
  35. AIDS Care. 2010 Nov;22(11):1305-13 - PubMed
  36. Drug Alcohol Depend. 2012 Jun 1;123(1-3):122-31 - PubMed
  37. Int J Drug Policy. 2007 Oct;18(5):437-43 - PubMed
  38. J Hepatol. 2006 Oct;45(4):529-38 - PubMed
  39. Gastroenterology. 2010 Feb;138(2):513-21, 521.e1-6 - PubMed
  40. Am J Prev Med. 2006 Dec;31(6):492-8 - PubMed
  41. J Infect Dis. 2011 Jul 1;204(1):74-83 - PubMed
  42. Hepatology. 2012 Jan;55(1):49-57 - PubMed
  43. J Theor Biol. 2011 Apr 7;274(1):58-66 - PubMed
  44. Liver Int. 2009 Aug;29(7):1051-5 - PubMed
  45. Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S339-45 - PubMed
  46. Clin Infect Dis. 2013 Oct;57(7):1014-20 - PubMed
  47. J Viral Hepat. 2009 May;16(5):352-8 - PubMed
  48. J Hepatol. 2011 Jun;54(6):1137-44 - PubMed
  49. Addiction. 2011 Nov;106(11):1978-88 - PubMed
  50. Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S373-8 - PubMed
  51. Drug Alcohol Depend. 2010 Jun 1;109(1-3):248-51 - PubMed
  52. J Subst Abuse Treat. 2003 Jun;24(4):291-7 - PubMed
  53. Eur J Gastroenterol Hepatol. 2007 Sep;19(9):741-7 - PubMed
  54. Eur J Gastroenterol Hepatol. 2011 Jan;23(1):23-31 - PubMed
  55. Eur J Gastroenterol Hepatol. 2010 Mar;22(3):270-7 - PubMed
  56. PLoS One. 2011;6(11):e27555 - PubMed
  57. Gastroenterology. 2010 Jan;138(1):123-35.e1-2 - PubMed
  58. Addiction. 2012 Nov;107(11):1984-95 - PubMed
  59. J Viral Hepat. 2006 Jan;13(1):34-41 - PubMed
  60. Int J Drug Policy. 2007 Oct;18(5):447-51 - PubMed
  61. Liver Int. 2012 Feb;32 Suppl 1:2-8 - PubMed
  62. JAMA. 1994 Jan 12;271(2):115-20 - PubMed
  63. Cent Eur J Public Health. 2012 Sep;20(3):223-5 - PubMed
  64. Hepatology. 2002 Nov;36(5 Suppl 1):S210-9 - PubMed
  65. Subst Use Misuse. 2010 May;45(6):813-64 - PubMed
  66. Am J Gastroenterol. 2008 May;103(5):1283-97; quiz 1298 - PubMed
  67. Ther Clin Risk Manag. 2010 Apr 26;6:207-12 - PubMed
  68. J Subst Abuse Treat. 2002 Mar;22(2):55-62 - PubMed
  69. Liver Int. 2009 Jan;29 Suppl 1:89-99 - PubMed
  70. Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1057-63 - PubMed
  71. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 15;18(5):505-11 - PubMed
  72. Drug Alcohol Depend. 2007 Apr 17;88(1):49-53 - PubMed
  73. Semin Liver Dis. 2011 Nov;31(4):340-6 - PubMed
  74. N Engl J Med. 2002 Sep 26;347(13):975-82 - PubMed
  75. Curr Drug Abuse Rev. 2008 Jun;1(2):177-87 - PubMed
  76. J Hepatol. 2010 Aug;53(2):245-51 - PubMed
  77. J Community Health. 2008 Jun;33(3):126-33 - PubMed
  78. Emerg Themes Epidemiol. 2013 Feb 02;10(1):1 - PubMed
  79. J Manag Care Pharm. 2011 Nov;17(9):685-94 - PubMed
  80. Bratisl Lek Listy. 2009;110(2):77-84 - PubMed
  81. J Clin Pharmacol. 2004 Jan;44(1):20-9 - PubMed
  82. Hepatology. 2013 Apr;57(4):1333-42 - PubMed
  83. Aliment Pharmacol Ther. 2009 Jul;30(1):14-27 - PubMed
  84. J Infect Dis. 2013 Mar;207 Suppl 1:S19-25 - PubMed
  85. Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1050-7 - PubMed
  86. Drug Alcohol Depend. 2011 Jan 15;113(2-3):83-5; discussion 86-7 - PubMed
  87. Cochrane Database Syst Rev. 2011 Aug 10;(8):CD004145 - PubMed
  88. Lancet Infect Dis. 2012 May;12(5):408-14 - PubMed
  89. Eur Addict Res. 2002 Jan;8(1):45-9 - PubMed
  90. World J Gastroenterol. 2007 May 7;13(17):2436-41 - PubMed
  91. Med Microbiol Immunol. 2011 Feb;200(1):7-11 - PubMed
  92. N Engl J Med. 2011 Jun 23;364(25):2429-38 - PubMed
  93. Clin Pharmacol Ther. 2012 Sep;92(3):294-305 - PubMed
  94. J Viral Hepat. 2007 Nov;14 Suppl 1:82-8 - PubMed
  95. Clin Infect Dis. 2013 Aug;57 Suppl 2:S129-37 - PubMed
  96. Liver Int. 2011 Jan;31 Suppl 1:62-7 - PubMed
  97. Bull Soc Pathol Exot. 1998;91(1):29-33 - PubMed
  98. Lancet. 2009 Jun 20;373(9681):2090-1 - PubMed

Publication Types